SubscribeThe HemoCue Albumin systems can be used for the quantitative determination of low levels of albumin in urine for the purpose of screening for, diagnosing, monitoring and supporting the clinical evidence in the treatment of microalbuminuria.
The system consists of a photometer and individually packaged microcuvettes. The reaction in the cuvette is based on a immunoturbidimetric reaction. The turbidity once formed is measured photometrically at 610 nm.
With three simple steps a quantitative result is achieved within 90 seconds!
Key benefits 
- Excellent precision and accuracy
- Quantitative results within 90 seconds
- Factory calibrated instrument
- Measurement range 5-150 mg/L without dilution. Samples up to and including 2000 mg/L can be obtained with samples diluted with isotonic sodium chloride
- The analysis can be performed with spot urine, preferably first morning urine, as well as urine collected overnight or during 24 hours
- Minimal maintenance
- Can be used by non-laboratory personnel after a brief training session
Clinical Applications
General Practice
Measurement of low levels of albumin in urine, microalbuminuria, is a useful tool to direct treatment in diabetes and hypertension. It is the earliest sign of renal or vasuclar damage - when no other physical signs are present to alert the physician about the condition.
International guidelines recommends annual screening for microalbuminuria in individuals with type 1 diabetes after five years with the disease and from the time of diagnosis for people with type 2 diabetes.
Diabetes Care
People with diabetes are at higher risk of developing micro and macrovascular complications in comparison with healthy subjects. Microalbuminuria is the earliest sign of renal dysfunction and an indication of disease progression. Multiple studies conclude that the presence of persistent microalbuminuria strongly predicts those who will eventually develop diabetic nephropathy. Patients with a persistent microalbuminuria have a twenty-fold increased risk of developing diabetic nephropathy and international guidelines recommends annual screening for microalbuminuria for early determination as to which patients require intervention.
Read more in our brochure Three vital tests in Diabetes Care
A call to action
Because microalbuminuria is such a clear risk marker for CKD and CVD, the potential benefits
of screening for it are enormous. If people with diabetes, people with hypertension and eventually
the general population were proactively screened, human suffering and health care spending could
be greatly reduced. Today, however, only a relatively small proportion of people known to have
type 2 diabetes or hypertension are regularly tested for the presence of microalbuminuria.
Read more in our brochure on Microalbuminuria - The true marker for early detection of cardiovascular/renal disease